Clinical Trial Shows Significant Benefits of Norwegian Sensometrics® Technology
Oslo University Hospital - Rikshospitalet Integrates Sensometrics Based on Trial Results
Oslo, Norway – dPCom A/S, producer of Sensometrics Technology, is pleased to announce the results of a recent clinical trial at the Oslo University Hospital – Rikshospitalet which indicate that patients with intracranial aneurysm bleeds treated with Sensometrics Technology were more than three times as likely to recover completely as compared to patients treated with traditional methods. Based on the findings, the hospital will integrate Sensometrics as its new, standard treatment method.
“We are very happy to see that Sensometrics performed so well in the clinical trial,” says Trond Stadheim, CEO, dPCom. “Our company has the potential to help numerous patients enjoy recovery through pressure monitoring technology, and we look forward to working with Oslo University Hospital and future partners to make this recovery a reality.” The randomized, blinded study included 97 patients who were referred to the Neurosurgery Department between 2005 and 2008 for intracranial aneurysm bleed (subarachnoid hemorrhage). The patients were randomized into two groups, one receiving traditional therapy and the other receiving dPCom’s Sensometrics Technology.
The results of the study, which are published in the November, 2011, issue of NEUROSURGERY, show that 1 in 3 in the Sensometrics group recovered completely, compared with1 in 10 in the group treated by traditional practices. Physicians at Oslo University Hospital were impressed by the performance of Sensometrics. “The results of the study represent a breakthrough in our field and have the potential to change the industry standard for patient treatment,” states Dr. Wilhelm Sorteberg, Head of Vascular Neurosurgery, Department of Neurosurgery, Oslo University Hospital. Regarding the decision to integrate Sensometrics Technology as standard practice, he adds, “These results are convincing and cannot be ignored. It is our responsibility to offer our patients the best possible chance of a full recovery, and Sensometrics clearly enhances their prognoses.”
Sensometrics® Technology is produced by dPCom, a Norwegian medical technology company founded in 2001. The technology provides safe diagnostic information from intracranial and blood pressure monitoring and is of particular significance for the management of patients with hydrocephalus, head injury, stroke, dementia, chronic headache, brain tumors, and diseases caused by arterial hypertension. It identifies the cardiac-induced pressure waves from various locations, including non-invasive surface locations, and is the leading technology today for dynamic invasive and non-invasive pressure monitoring. Sensometrics® Technology is CE certified and has US clearance from the FDA.
dPCom A/S is a Norwegian medical technology company, which allows healthcare professionals to safely and accurately monitor pressures in patients. The company has developed a new innovative technology that significantly improves the diagnostic information from invasive and non-invasive pressure measurements, focusing on intracranial pressure (ICP) and blood pressure (ABP). The new method is suitable for use in intensive care units (ICU) for the monitoring of brain disease/injury, and for diagnostic pressure monitoring in general. Sensometrics® Technology significantly improves pressure diagnostics for healthcare professionals and has a leading role in non-invasive intracranial pressure diagnostics.
dPCom A/S was founded in 2001 after physicians at The National Hospital (Rikshospitalet) in Oslo discovered problems with traditional pressure monitoring methodology. A series of clinical studies have since been carried out , and numerous scientific articles documenting the weaknesses of traditional measuring methods have been published.
Sensometrics® Software is compatible with several industrial pressure measuring devices, and is CE certified and has received US clearance from the FDA. The technology is protected by several patents.
Sensometrics® and Always safe pressure diagnostics™ are registered trademarks.
Sensometrics® Technology provides safe diagnostic information from intracranial and blood pressure monitoring. The technology is of particular significance for the management of patients with hydrocephalus, head injury, stroke, dementia, chronic headache, brain tumors, and diseases caused by arterial hypertension. Sensometrics® Technology identifies the cardiac-induced pressure waves from various locations, including non-invasive surface locations, and is the leading technology today for dynamic invasive and non-invasive pressure monitoring.